Trade Elicit Therapeutics Inc. - ELTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0810 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023485% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001262% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6.1395 |
| Open | 5.7895 |
| 1-Year Change | -23.57% |
| Day's Range | 4.9895 - 5.7895 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 6.1395 | -1.2500 | -16.92% | 7.3895 | 7.3895 | 6.1395 |
| Mar 28, 2025 | 7.7695 | 0.0800 | 1.04% | 7.6895 | 8.0395 | 7.5895 |
| Mar 27, 2025 | 7.6495 | -0.3400 | -4.26% | 7.9895 | 7.9895 | 7.4795 |
| Mar 26, 2025 | 7.9895 | -0.1500 | -1.84% | 8.1395 | 8.1895 | 7.9895 |
| Mar 25, 2025 | 8.2895 | 0.0000 | 0.00% | 8.2895 | 8.3895 | 8.1795 |
| Mar 24, 2025 | 8.4895 | -0.3000 | -3.41% | 8.7895 | 8.7895 | 8.2895 |
| Mar 21, 2025 | 8.4895 | 0.4000 | 4.94% | 8.0895 | 8.7195 | 8.0895 |
| Mar 20, 2025 | 8.1095 | 0.5200 | 6.85% | 7.5895 | 8.2895 | 7.5895 |
| Mar 19, 2025 | 7.8295 | 0.0600 | 0.77% | 7.7695 | 8.0495 | 7.5895 |
| Mar 18, 2025 | 7.8095 | -0.0400 | -0.51% | 7.8495 | 7.9695 | 7.4895 |
| Mar 17, 2025 | 7.8295 | 0.0900 | 1.16% | 7.7395 | 7.8595 | 7.6995 |
| Mar 14, 2025 | 7.7295 | -0.2200 | -2.77% | 7.9495 | 7.9495 | 7.3895 |
| Mar 13, 2025 | 7.8795 | 0.3300 | 4.37% | 7.5495 | 7.8795 | 7.5495 |
| Mar 12, 2025 | 7.8095 | 0.0900 | 1.17% | 7.7195 | 7.9595 | 7.6695 |
| Mar 11, 2025 | 7.5095 | 0.0900 | 1.21% | 7.4195 | 7.7295 | 7.4195 |
| Mar 10, 2025 | 7.6395 | 0.0500 | 0.66% | 7.5895 | 7.6595 | 7.4895 |
| Mar 7, 2025 | 7.7395 | -0.2200 | -2.76% | 7.9595 | 7.9595 | 7.5195 |
| Mar 6, 2025 | 7.9595 | 0.0200 | 0.25% | 7.9395 | 8.3595 | 7.8995 |
| Mar 5, 2025 | 8.3195 | 0.4800 | 6.12% | 7.8395 | 8.3595 | 7.8395 |
| Mar 4, 2025 | 8.0695 | 0.2400 | 3.07% | 7.8295 | 8.1095 | 7.4595 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Angion Biomedica Corp. Company profile
About Angion Biomedica Corp
Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
451 D Street, 5Th Floor
BOSTON
MASSACHUSETTS 02459
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com